Zevra Therapeutics (ZVRA) Exchange Rate Effect (2022 - 2026)
Zevra Therapeutics' (ZVRA) quarterly Exchange Rate Effect came in at $233000.0 in Q1 2026, up 162.63% YoY from $88716.5 in Q1 2025, and up 172.36% on a QoQ basis from -$322000.0 in Q4 2025.
Powered by 
Analysis
Zevra Therapeutics (ZVRA) Exchange Rate Effect (2022 - 2026) Analysis & Trends
Zevra Therapeutics (ZVRA) has 5 years of Exchange Rate Effect data on file, last reported at $233000.0 in Q1 2026.
- Quarterly Exchange Rate Effect rose 162.63% year-over-year to $233000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $633000.0 (up 398.43% YoY) and the FY2025 annual result came in at $28000.0, down 93.83% from the prior year.
- Exchange Rate Effect climbed to $233000.0 in Q1 2026, from -$322000.0 in the prior quarter.
- In the past five years, Exchange Rate Effect ranged from a high of $671000.0 in Q4 2024 to a low of -$491000.0 in Q3 2024.
- A 5-year average of $64200.0 and a median of $64000.0 in 2025 frame the typical range for Exchange Rate Effect.
- Annual changes were most pronounced in 2023 — Exchange Rate Effect sank 780.0% — and 2024, when it jumped 219.03%.
- Tracing ZVRA's Exchange Rate Effect over 5 years: stood at $189000.0 in 2022, then jumped by 84.66% to $349000.0 in 2023, then jumped by 92.26% to $671000.0 in 2024, then plunged by 147.99% to -$322000.0 in 2025, then jumped by 172.36% to $233000.0 in 2026.
- The last three Exchange Rate Effect figures came in at $233000.0 (Q1 2026), -$322000.0 (Q4 2025), and $64000.0 (Q3 2025), per Business Quant data.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Exchange Rate Effect (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn | -3.70 Mn |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn | -300,000.00 |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn | -2.00 Mn |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - | - |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn | 19.84 Mn |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn | -2.45 Mn |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - | - |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | -287,000.00 |
| 10 | Zevra Therapeutics | 734.60 Mn | 513.03 Mn | 38.18 Mn | -342,000.00 |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | -342,000.00 |
| Mar 31, 2026 | 233,000.00 |
| Dec 31, 2025 | -322,000.00 |
| Sep 30, 2025 | 64,000.00 |
| Jun 30, 2025 | 658,000.00 |
| Mar 31, 2025 | -372,000.00 |
| Dec 31, 2024 | 671,000.00 |
| Sep 30, 2024 | -491,000.00 |
| Jun 30, 2024 | 319,000.00 |
| Mar 31, 2024 | -45,000.00 |
| Dec 31, 2023 | 349,000.00 |
| Sep 30, 2023 | -102,000.00 |
| Jun 30, 2023 | -268,000.00 |
| Mar 31, 2023 | 65,000.00 |
| Dec 31, 2022 | 189,000.00 |
| Sep 30, 2022 | 15,000.00 |